Predicted strain coverage of a new protein-based meningococcal vaccine in the czech republic;Očekávané pokrytí kmenů novou proteinovou meningokokovou vakcínou v České republice

Epidemiologie, Mikrobiologie, Imunologie

Volumn 63, Issue 2, 2014, Pages 103-106

  Krizova P ^a   Musilek M ^a   Vackova Z ^a   Kozakova J ^a   Claus, H ^b   Vogel, U ^b   Medini, D ^c  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

MATS; MenB vaccine; Meningococcal Antigen Typing System; Neisseria meningitidis B; Vaccine coverage

Indexed keywords

BACTERIAL ANTIGEN; MENINGOCOCCUS VACCINE;

ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CZECH REPUBLIC; IMMUNOLOGICAL PROCEDURES; MENINGOCOCCAL ANTIGEN TYPING SYSTEM; NEISSERIA MENINGITIDIS; NONHUMAN; PREDICTION; CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY;

ANTIGENS, BACTERIAL; CZECH REPUBLIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS;

EID: 84923377437     PISSN: 12107913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. http://www.ecdc.europa.eu/en/publications/Publications/AnnualEpidemiological-Report-2012.pdf. Access: December 29, 2013.
2. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine, 2009;27(2):B51–63.
3. Halperin SA, Bettinger JA, Greenwood,B et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine, 2012;30(2):B26–36.
4. Křížová P, Vacková Z, Musílek M, Kozáková J. Invazivní meningokokové onemocnění v České republice – surveillance a doporučení k vakcinační strategii. Epidemiologie, mikrobiologie, imunologie, 2013;62(4):138–147.
5. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol, 2000;3(5):445–450.
6. Rappuoli R, Covacci A. Reverse vaccinology and genomics. Science, 2003;302(5645):602.
7. Serruto D, Bottomley MJ, Ram S et al. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of antigens. Vaccine, 2012;30Suppl 2:B87–97.
8. Donnelly J, Medini D, Boccadifuoco G et al. Qualitative and quantitative assessment of meningococcal antigens to evaluace the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA, 2010;107(45):19490–19495.
9. Vogel U, Taha MK, Vazquez JA et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis, 2013;13(5):416–425.
10. http://pubmlst.org/neisseria/ Access: December 29, 2013.
11. Plikaytis BD, Stella M, Boccadifuoco G et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clinical and Vaccine Imunology, 2012;19:1609–1617.
12. Frosi G, Biolchi A, Lo Sapio M et al. Bactericidal antipody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine, 2013;31(43):4968–49674.
13. http://emgm.eu/downloads/Statement_of_the_EMGM_Society_on_Bexsero_final_Jan_25_13.pdf. Access: December 29, 2013.